» Articles » PMID: 9657527

Skeletal Muscle Myocytes Undergo Protein Loss and Reactive Oxygen-mediated NF-kappaB Activation in Response to Tumor Necrosis Factor Alpha

Overview
Journal FASEB J
Specialties Biology
Physiology
Date 1998 Jul 10
PMID 9657527
Citations 174
Authors
Affiliations
Soon will be listed here.
Abstract

Skeletal muscle atrophy and weakness are thought to be stimulated by tumor necrosis factor alpha (TNF-alpha) in a variety of chronic diseases. However, little is known about the direct effects of TNF-alpha on differentiated skeletal muscle cells or the signaling mechanisms involved. We have tested the effects of TNF-alpha on the mouse-derived C2C12 muscle cell line and on primary cultures from rat skeletal muscle. TNF-alpha treatment of differentiated myotubes stimulated time- and concentration-dependent reductions in total protein content and loss of adult myosin heavy chain (MHCf) content; these changes were evident at low TNF-alpha concentrations (1-3 ng/ml) that did not alter muscle DNA content and were not associated with a decrease in MHCf synthesis. TNF-alpha activated binding of nuclear factor kappaB (NF-kappaB) to its targeted DNA sequence and stimulated degradation of I-kappaBalpha, an NF-kappaB inhibitory protein. TNF-alpha stimulated total ubiquitin conjugation whereas a 26S proteasome inhibitor (MG132 10-40 microM) blocked TNF-alpha activation of NF-kappaB. Catalase 1 kU/ml inhibited NF-kappaB activation by TNF-alpha; exogenous hydrogen peroxide 200 microM activated NF-kappaB and stimulated I-kappaBalpha degradation. These data demonstrate that TNF-alpha directly induces skeletal muscle protein loss, that NF-kappaB is rapidly activated by TNF-alpha in differentiated skeletal muscle cells, and that TNF-alpha/NF-kappaB signaling in skeletal muscle is regulated by endogenous reactive oxygen species.

Citing Articles

Screening of hub genes for sepsis-induced myopathy by weighted gene co-expression network analysis and protein-protein interaction network construction.

Wang J, Han K, Lu J BMC Musculoskelet Disord. 2024; 25(1):834.

PMID: 39438952 PMC: 11494751. DOI: 10.1186/s12891-024-07967-0.


The Role of Non-Coding RNAs in Regulating Cachexia Muscle Atrophy.

Chen G, Zou J, He Q, Xia S, Xiao Q, Du R Cells. 2024; 13(19.

PMID: 39404384 PMC: 11482569. DOI: 10.3390/cells13191620.


Immune mediators in heart-lung communication.

Gillan J, Jaeschke L, Kuebler W, Grune J Pflugers Arch. 2024; 477(1):17-30.

PMID: 39256247 PMC: 11711577. DOI: 10.1007/s00424-024-03013-z.


Extracellular vesicles in cancer cachexia: deciphering pathogenic roles and exploring therapeutic horizons.

Wang Y, Ding S J Transl Med. 2024; 22(1):506.

PMID: 38802952 PMC: 11129506. DOI: 10.1186/s12967-024-05266-9.


Transcriptome-based deep learning analysis identifies drug candidates targeting protein synthesis and autophagy for the treatment of muscle wasting disorder.

Lee M, Lee B, Park S, Yang G, Cheon S, Lee D Exp Mol Med. 2024; 56(4):904-921.

PMID: 38556548 PMC: 11059359. DOI: 10.1038/s12276-024-01189-z.